Publications

Journal Article
Review
Epublish 28 citations
Open access — free full text available
Open access
Electronic publication date
October 29, 2022

View on Pubmed.gov 36287277 | View on doi.org 10.1007/s00018-... | View the free full text Full text

Anthracycline-induced cardiotoxicity and cell senescence: new therapeutic option?

Search for publications in this journal Cell Mol Life Sci - 79(11):568

Abstract

Anthracyclines are chemotherapeutic drugs widely used in the frontline of cancer treatment. The therapeutic mechanisms involve the stabilization of topoisomerase IIα, DNA, and the anthracycline molecule in a ternary complex that is recognized as DNA damage. Redox imbalance is another vital source of oxidative DNA damage. Together, these mechanisms lead to cytotoxic effects in neoplastic cells. However, anthracycline treatment can elicit cardiotoxicity and heart failure despite the therapeutic benefits. Topoisomerase IIβ and oxidative damage in cardiac cells have been the most reported pathophysiological mechanisms. Alternatively, cardiac cells can undergo stress-induced senescence when exposed to anthracyclines, a state primarily characterized by cell cycle arrest, organelle dysfunction, and a shift to senescence-associated secretory phenotype (SASP). The SASP can propagate senescence to neighboring cells in an ongoing process that leads to the accumulation of senescent cells, promoting cellular dysfunction and extracellular matrix remodeling. Therefore, the accumulation of senescent cardiac cells is an emerging pathophysiological mechanism associated with anthracycline-induced cardiotoxicity. This paradigm also raises the potential for therapeutic approaches to clear senescent cells in treating anthracycline-induced cardiotoxicity (i,e, senolytic therapies).

References

Annu Rev Pathol. 2010;5:99-118

FEMS Microbiol Rev. 2008 Aug;32(5):858-89

J Am Heart Assoc. 2016 Jan 08;5(1):

Nature. 2016 Feb 11;530(7589):184-9

Cited by 28 citations (total)

Journal Article

Pleiotropic Multi-Drug Co-Assembled Nanocomposites Offer Protection Against Doxorubicin-Induced Cardiotoxicity.

Electronic publication date July 30, 2025

Search for publications in this journal Int J Nanomedicine

Dan Yin [...] Jie Tian et al.

Background

Doxorubicin (DOX) is a first-line chemotherapeutic agent, yet its clinical utility is limited by doxorubicin-induced cardiotoxicity (DIC), a dose-dependent side...

Journal Article Meta-Analysis Systematic Review Research Support, Non-U.S. Gov't

Effects of Physical Activity on Cardiotoxicity and Cardio respiratory Function in Cancer Survivors Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.

Electronic publication date October 17, 2024

Search for publications in this journal Integr Cancer Ther

Kang Chen [...] He Zhuang et al.

Physical activity, as a promising complementary therapy, has shown considerable potential for reducing chemotherapy-related cardiotoxicity (CTRCT) and enhancing cardiorespiratory function...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.